Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...
(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...
The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...
Here's what's new in Bay Area biz news to start your workweek: tech stocks on wild ride, empty S.F. office buildings, copper ...
GlobalData on MSN1d
GLP-1RA developer Metsera targets $289m IPOMetsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback